According to SCYNEXIS's latest financial reports the company's current revenue (TTM) is $0.14 B. In 2022 the company made a revenue of $5.09 M a decrease over the years 2021 revenue that were of $13.16 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.14 B | 2652.74% |
2022 | $5.09 M | -61.32% |
2021 | $13.16 M | |
2020 | N/A | -100% |
2019 | $0.12 M | -52.73% |
2018 | $0.25 M | 0% |
2017 | $0.25 M | 0% |
2016 | $0.25 M | -0.39% |
2015 | $0.25 M | -97.46% |
2014 | $10.12 M | -39.92% |
2013 | $16.85 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Galmed Pharmaceuticals
GLMD | N/A | N/A | ๐ฎ๐ฑ Israel |
Catalyst Pharmaceuticals CPRX | $0.39 B | 184.14% | ๐บ๐ธ USA |
Catalent CTLT | $4.09 B | 2,824.18% | ๐บ๐ธ USA |
KemPharm KMPH | $10.45 M | -92.54% | ๐บ๐ธ USA |